Atossa Genetics: Seeking To Prevent Or Treat Breast Cancer
Edison | Nov 16, 2017 08:07AM ET
Atossa Genetics Inc (NASDAQ:ATOS) reported Phase I data on its topical endoxifen formulation and it is now developing this as a potential treatment for high mammographic breast density (MBD), which is associated with increased breast cancer risk. The firm is also developing oral endoxifen for patients refractory to tamoxifen, and its intraductal microcatheter (IDMC), combined with established cancer drug fulvestrant. After also considering the recent $5.5m equity raise (at $0.44 per share), our rNPV-derived equity valuation is $24.6m (from $9.3m previously), or $0.93 per share.
Topical endoxifen targets high breast density
Oral tamoxifen, a selective estrogen receptor modulation (SERM) drug, reduces both MBD and the risk of cancer recurrence in women with breast cancer, but its adverse effects (AE) have limited its use. Endoxifen is a tamoxifen metabolite that is responsible for much of the oral drug’s SERM action. Atossa believes that topical endoxifen can exert SERM effects to breast tissue and reduce MBD, with fewer significant AE. Following its Phase I study showing early safety and signs of dose-dependent absorption, Atossa plans to start a 480-patient Phase II trial in Q118.
To read the entire report Please click on the pdf File Below:
Seeking To Prevent Or Treat Breast Cancer
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.